CLSA Raises Wuxi Apptec Price Target to HK$149.3, Keeps Outperform Rating

Deep News04-25 11:00

CLSA has released a research report stating that Wuxi Apptec (02359, 603259.SH) is set to announce its first-quarter results next Monday (27th), with expectations of accelerating profit momentum, an improving business mix, and room for valuation re-rating. The firm maintained its "Outperform" rating for both the H-shares and A-shares. The target price for H-shares was raised from HK$144.4 to HK$149.3, while the target price for A-shares was increased from RMB 126.7 to RMB 130.9, based on an unchanged forecasted price-to-earnings ratio of 20 times for 2027.

The report forecasts that Wuxi Apptec's first-quarter revenue will grow 20% year-on-year, with revenue from continuing operations rising 25% year-on-year. High-margin TIDES business and the divestiture of low-growth clinical CRO operations are expected to drive adjusted non-IFRS net profit growth of over 35% year-on-year. CLSA has raised its revenue and profit forecasts for Wuxi Apptec for 2026 to 2028 by 1% and 3%, respectively, reflecting strong visibility. As of the fourth quarter of 2025, the company's order backlog reached RMB 58 billion, up 29% year-on-year, supporting a 22% year-on-year growth in revenue from continuing operations for 2026, which is at the upper end of management's guidance range of 18% to 22% growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108414710?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-25 11:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108414710","market":"other","top_or_hot":-1,"title":"CLSA Raises Wuxi Apptec Price Target to HK$149.3, Keeps Outperform Rating","media":"Deep News","content":"<p>CLSA has released a research report stating that Wuxi Apptec (02359, 603259.SH) is set to announce its first-quarter results next Monday (27th), with expectations of accelerating profit momentum, an improving business mix, and room for valuation re-rating. The firm maintained its \"Outperform\" rating for both the H-shares and A-shares. The target price for H-shares was raised from HK$144.4 to HK$149.3, while the target price for A-shares was increased from RMB 126.7 to RMB 130.9, based on an unchanged forecasted price-to-earnings ratio of 20 times for 2027.</p>\n<p>The report forecasts that Wuxi Apptec's first-quarter revenue will grow 20% year-on-year, with revenue from continuing operations rising 25% year-on-year. High-margin TIDES business and the divestiture of low-growth clinical CRO operations are expected to drive adjusted non-IFRS net profit growth of over 35% year-on-year. CLSA has raised its revenue and profit forecasts for Wuxi Apptec for 2026 to 2028 by 1% and 3%, respectively, reflecting strong visibility. As of the fourth quarter of 2025, the company's order backlog reached RMB 58 billion, up 29% year-on-year, supporting a 22% year-on-year growth in revenue from continuing operations for 2026, which is at the upper end of management's guidance range of 18% to 22% growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLSA Raises Wuxi Apptec Price Target to HK$149.3, Keeps Outperform Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLSA Raises Wuxi Apptec Price Target to HK$149.3, Keeps Outperform Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-04-25 11:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLSA has released a research report stating that Wuxi Apptec (02359, 603259.SH) is set to announce its first-quarter results next Monday (27th), with expectations of accelerating profit momentum, an improving business mix, and room for valuation re-rating. The firm maintained its \"Outperform\" rating for both the H-shares and A-shares. The target price for H-shares was raised from HK$144.4 to HK$149.3, while the target price for A-shares was increased from RMB 126.7 to RMB 130.9, based on an unchanged forecasted price-to-earnings ratio of 20 times for 2027.</p>\n<p>The report forecasts that Wuxi Apptec's first-quarter revenue will grow 20% year-on-year, with revenue from continuing operations rising 25% year-on-year. High-margin TIDES business and the divestiture of low-growth clinical CRO operations are expected to drive adjusted non-IFRS net profit growth of over 35% year-on-year. CLSA has raised its revenue and profit forecasts for Wuxi Apptec for 2026 to 2028 by 1% and 3%, respectively, reflecting strong visibility. As of the fourth quarter of 2025, the company's order backlog reached RMB 58 billion, up 29% year-on-year, supporting a 22% year-on-year growth in revenue from continuing operations for 2026, which is at the upper end of management's guidance range of 18% to 22% growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1808992512.USD","symbol_name":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1108414710","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108414710","pubTimestamp":1777086051,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"CLSA has released a research report stating that Wuxi Apptec (02359, 603259.SH) is set to announce its first-quarter results next Monday (27th), with expectations of accelerating profit momentum, an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","BK1141":"生命科学工具和服务","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1576":"医药外包概念","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","EWH":"香港ETF-iShares MSCI","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","BK0216":"研究试验","BK1583":"高瓴概念","LU1997245177.USD":"安联神洲A股基金","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","02359":"药明康德","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"里昂证券上调药明康德目标价至149.3港元维持跑赢大市评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1,"EWH":1,"02359":1},"content_text":"CLSA has released a research report stating that Wuxi Apptec (02359, 603259.SH) is set to announce its first-quarter results next Monday (27th), with expectations of accelerating profit momentum, an improving business mix, and room for valuation re-rating. The firm maintained its \"Outperform\" rating for both the H-shares and A-shares. The target price for H-shares was raised from HK$144.4 to HK$149.3, while the target price for A-shares was increased from RMB 126.7 to RMB 130.9, based on an unchanged forecasted price-to-earnings ratio of 20 times for 2027.\nThe report forecasts that Wuxi Apptec's first-quarter revenue will grow 20% year-on-year, with revenue from continuing operations rising 25% year-on-year. High-margin TIDES business and the divestiture of low-growth clinical CRO operations are expected to drive adjusted non-IFRS net profit growth of over 35% year-on-year. CLSA has raised its revenue and profit forecasts for Wuxi Apptec for 2026 to 2028 by 1% and 3%, respectively, reflecting strong visibility. As of the fourth quarter of 2025, the company's order backlog reached RMB 58 billion, up 29% year-on-year, supporting a 22% year-on-year growth in revenue from continuing operations for 2026, which is at the upper end of management's guidance range of 18% to 22% growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108414710","isCrawlerRequest":true}